Overall rank by patents
#25,666
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California
USPTO PatentsView assignee record - 10 granted patents across 10 technology areas, active 2015–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
10
Total patents granted
10
CPC technology areas
22.0
Avg claims per patent
+50%
5-year filing velocity
The verdict
Alfred holds 10 US patents across 10 technology areas, rank #25,666 of 50,000 tracked assignees.
- #25,666
- of 50,000 US assignees by volume
- Top 22%
- by Innovation Score (46.0/100)
- 22.0
- avg claims per patent
- +50%
- filing velocity, last 5 yrs
Portfolio overview
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California has been granted 10 US utility patents between 2015 and 2023, placing Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California at rank #25,666 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.0 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California is one of the more focused assignees in the PatentsView dataset. By volume, Alfred sits between Albaad Massuot Yitzhak Ltd (10 patents, rank #25,662) and Allied Moulded Products, Inc. (10 patents, rank #25,670) - the closest US assignees by grant volume. The composite Innovation Score of 46.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 4 in the 2015–2019 window, a +50% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's 22.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California against peers pursuing similar technology classes.
Who files at Alfred's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Albaad Massuot Yi…
ALBAAD MASSUOT YITZHAK LTD
10 patents
- ALC Holdings
ALC HOLDINGS, INC.
10 patents
- ALFA Wassermann
ALFA WASSERMANN, INC.
10 patents
- Alfdex AB
ALFDEX AB
10 patents
- Alfred-wegener-in…
ALFRED-WEGENER-INSTITUT, HELMHOLTZ-ZENTRUM FUER POLAR—UND MEERESFORSCHUNG
10 patents
- Alken
ALKEN Inc.
10 patents
- Allen-vanguard
ALLEN-VANGUARD CORPORATION
10 patents
- Allied Moulded Pr…
ALLIED MOULDED PRODUCTS, INC.
10 patents
- Alfred E MANN Ins… ◀
ALFRED E. MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA
10 patents
What this shows Alfred holds 10 patents at rank #25,666, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Alfred's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 20.0% |
| 2016 | 1 | 10.0% |
| 2018 | 1 | 10.0% |
| 2020 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
| 2022 | 2 | 20.0% |
| 2023 | 2 | 20.0% |
Which technologies does Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California patent most?
Top 10 of 10 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California hold?
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California holds 10 US granted patents filed between 2015 and 2023, spanning 10 technology areas.
What is Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's Innovation Score?
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California has an Innovation Score of 46.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California focus on?
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 4 patents. The company has filed patents in 10 CPC subclasses total.
Is Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's patent filing rate increasing or decreasing?
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's recent filing velocity is +50% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's patents?
Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California's patents average 22.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Alfred E. MANN Institute FOR Biomedical Engineering AT THE University OF Southern California patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Alfred's 10 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Alfred ranks #25,666 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61B - see who else leads that technology area. A61B leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.